Witnessing the stock’s movement on the chart, on Thursday, Black Diamond Therapeutics Inc (NASDAQ: BDTX) set off with pace as it heaved 3.37% to $2.76, before settling in for the price of $2.67 at the close. Taking a more long-term approach, BDTX posted a 52-week range of $1.20-$4.94.
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was -5.22%. Meanwhile, its Annual Earning per share during the time was -5.22%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 135.14%. This publicly-traded company’s shares outstanding now amounts to $56.94 million, simultaneously with a float of $44.75 million. The organization now has a market capitalization sitting at $157.25 million. At the time of writing, stock’s 50-day Moving Average stood at $3.79, while the 200-day Moving Average is $2.70.
Black Diamond Therapeutics Inc (BDTX) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Black Diamond Therapeutics Inc’s current insider ownership accounts for 21.46%, in contrast to 58.80% institutional ownership. According to the most recent insider trade that took place on Mar 19 ’25, this organization’s 10% Owner sold 5,784,292 shares at the rate of 2.07, making the entire transaction reach 11,997,749 in total value, affecting insider ownership by 2,733,547.
Black Diamond Therapeutics Inc (BDTX) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.06 per share during the current fiscal year.
Black Diamond Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 135.14% and is forecasted to reach -0.63 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 12.97% through the next 5 years, which can be compared against the -5.22% growth it accomplished over the previous five years trading on the market.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) Trading Performance Indicators
Let’s observe the current performance indicators for Black Diamond Therapeutics Inc (BDTX). It’s Quick Ratio in the last reported quarter now stands at 8.94. Alongside those numbers, its PE Ratio stands at $7.61, and its Beta score is 3.38. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.25. Similarly, its price to free cash flow for trailing twelve months is now 7.37.
In the same vein, BDTX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.36, a figure that is expected to reach -0.18 in the next quarter, and analysts are predicting that it will be -0.63 at the market close of one year from today.
Technical Analysis of Black Diamond Therapeutics Inc (BDTX)
Going through the that latest performance of [Black Diamond Therapeutics Inc, BDTX]. Its last 5-days volume of 1.37 million was inferior to the volume of 1.7 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 28.67% While, its Average True Range was 27.16.
Raw Stochastic average of Black Diamond Therapeutics Inc (BDTX) in the period of the previous 100 days is set at 19.85%, which indicates a major fall in contrast to 30.32% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.26 that was higher than 0.23 volatility it exhibited in the past 100-days period.
